The time has come: A new scene for PKU treatment

Genetics and Molecular Research

Volumn 5, Issue 1, 2006, Pages 33-44

  Dos Santos, Luciana Lara ^a   Magalhães, Myrian De Castro ^a   Januário, José Nélio ^a   Burle De Aguiar, Marcos José ^a   Carvalho, Maria Raquel Santos ^a  

^a FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

Author keywords

Gene therapy; Large neutral amino acids; Phenylalanine ammonia lyase; Phenylketonuria; PKU treatment; Tetrahydrobiopterin; Therapeutic strategies

Indexed keywords

AMINO ACID; BENZENE DERIVATIVE; COMPLEMENTARY DNA; GUANOSINE TRIPHOSPHATE CYCLOHYDROLASE I; PHENYLALANINE 4 MONOOXYGENASE; PHENYLALANINE AMMONIA LYASE; PROTEINASE INHIBITOR; TETRAHYDROBIOPTERIN; VITAMIN;

ADENOVIRUS VECTOR; AMINO ACID TRANSPORT; BLOOD BRAIN BARRIER; CATABOLISM; COST BENEFIT ANALYSIS; DIET RESTRICTION; DIET SUPPLEMENTATION; DRUG EFFICACY; ESCHERICHIA COLI; EXERCISE; GENE THERAPY; GENETIC CODE; GENETICS; HEALTH STATUS; HUMAN; IMMUNOGENICITY; LOADING TEST; MENTAL DEFICIENCY; METABOLISM; METHODOLOGY; MOLECULAR CLONING; PHENYLKETONURIA; PREGNANCY; PROTEIN DEGRADATION; PROTEIN DIET; PROTEIN RESTRICTION; RECOMBINANT GENE; RETROVIRUS VECTOR; REVIEW; SCREENING; THEORETICAL MODEL;

AMINO ACIDS; DIET, PROTEIN-RESTRICTED; FOOD; FOOD, FORMULATED; GENE THERAPY; HUMANS; PHENOTYPE; PHENYLALANINE; PHENYLALANINE HYDROXYLASE; PHENYLKETONURIAS; TASTE;

ADENOVIRIDAE; ESCHERICHIA COLI;

EID: 33644638058     PISSN: 16765680     EISSN: 16765680     Source Type: Journal    
DOI: None     Document Type: Review

References (79)

1. Acosta A, Silva Jr W, Carvalho T, Gomes M et al. (2001). Mutations of the phenylalanine hydroxylase (PAH) gene in Brazilian patients with phenylketonuria. Hum. Mutat. 17: 122-130.
2. Acosta PB, Yannicelli S, Singh R, Mofidi S et al. (2003). Nutrient intakes and physical growth of children with phenylketonuria undergoing nutrition therapy. J. Am. Diet. Assoc. 103: 1167-1173.
3. Arnold GL, Vladutiu CJ, Kirby RS, Blakely EM et al. (2002). Protein insufficiency and linear growth restriction in phenylketonuria. J. Pediatr. 141: 243-246.
4. Bardelli T, Donati MA, Gasperini S, Ciani F et al. (2002). Two novel genetic lesions and a common BH4-responsive mutation of the PAH gene in Italian patients with hyperphenylalaninemia. Mol. Genet. Metab. 77: 260-266.
5. Beasley MG, Costello PM and Smith I (1994). Outcome of treatment in young adults with phenylketonuria detected by routine neonatal screening between 1964 and 1971. Q. J. Med. 87: 155-160.
6. Bernegger C and Blau N (2002). High frequency of tetrahydrobiopterin- responsiveness among hyperphenylalaninemias: a study of 1,919 patients observed from 1988 to 2002. Mol. Genet. Metab. 77: 304-313.
7. Blau N and Erlandsen H (2004). The metabolic and molecular bases of tetrahydrobiopterin-responsive phenylalanine hydroxylase deficiency. Mol. Genet. Metab. 82: 101-111.
8. Cerone R, Schiaffino MC, Fantasia AR, Perfumo M et al. (2004). Long-term follow-up of a patient with mild tetrahydrobiopterin-responsive phenylketonuria. Mol. Genet. Metab. 81: 137-139.
9. Christ SE (2003). Asbjorn Folling and the discovery of phenylketonuria. J. Hist. Neurosci. 12: 44-54.
10. Christensen R, Kolvraa S, Blaese RM and Jensen TG (2000). Development of a skin-based metabolic sink for phenylalanine by overexpression of phenylalanine hydroxylase and GTP cyclohydrolase in primary human keratinocytes. Gene Ther. 7: 1971-1978.
11. Christensen R, Guttler F and Jensen TG (2002). Comparison of epidermal keratinocytes and dermal fibroblasts as potential target cells for somatic gene therapy of phenylketonuria. Mol. Genet. Metab. 76: 313-318.
12. Christensen R, Alhonen L, Wahlfors J, Jakobsen M et al. (2005a). Characterization of transgenic mice with the expression of phenylalanine hydroxylase and GTP cyclohydrolase I in the skin. Exp. Dermatol. 14: 535-542.
13. Christensen R, Kolvraa S and Jensen TG (2005b). Manipulation of the phenylalanine metabolism in human keratinocytes by retroviral mediated gene transfer. Cells Tissues Organs 179: 170-178.
14. Clague A and Thomas A (2002). Neonatal biochemical screening for disease. Clin. Chim. Acta 315: 99-110.
15. Clark AG (1998). Mutation-selection balance with multiple alleles. Genetica 102-103: 41-47.
16. Desviat LR, Perez B, Belanger-Quintana A, Castro M et al. (2004). Tetrahydrobiopterin responsiveness: results of the BH4 loading test in 31 Spanish PKU patients and correlation with their genotype. Mol. Genet. Metab. 83: 157-162.
17. Ding Z, Harding CO and Thony B (2004). State-of-the-art 2003 on PKU gene therapy. Mol. Genet. Metab. 81: 3-8.
18. Dipple KM and McCabe ER (2000). Phenotypes of patients with "simple" Mendelian disorders are complex traits: thresholds, modifiers, and systems dynamics. Am. J. Hum. Genet. 66: 1729-1735.
19. Eisensmith RC and Woo SL (1994). Gene therapy for phenylketonuria. Acta Paediatr. Suppl. 407: 124-129.
20. Eisensmith RC and Woo SL (1996). Gene therapy for phenylketonuria. Eur. J. Pediatr. 155 (Suppl 1): S16-S19.
21. Erlandsen H and Stevens RC (2001). A structural hypothesis for BH4 responsiveness in patients with mild forms of hyperphenylalaninaemia and phenylketonuria. J. Inherit. Metab. Dis. 24: 213-230.
22. Erlandsen H, Patch MG, Gamez A, Straub M et al. (2003). Structural studies on phenylalanine hydroxylase and implications toward understanding and treating phenylketonuria. Pediatrics 112: 1557-1565.
23. Fang B, Eisensmith RC, Li XH, Finegold MJ et al. (1994). Gene therapy for phenylketonuria: phenotypic correction in a genetically deficient mouse model by adenovirus-mediated hepatic gene transfer. Gene Ther. 1: 247-254.
24. Fisch RO (2000). Comments on diet and compliance in phenylketonuria. Eur. J. Pediatr. 159 (Suppl 2): S142-S144.
25. Gamez A, Sarkissian CN, Wang L, Kim W et al. (2005). Development of pegylated forms of recombinant Rhodosporidium toruloides phenylalanine ammonia-lyase for the treatment of classical phenylketonuria. Mol. Ther. 11: 986-989.
26. Gjetting T, Romstad A, Haavik J, Knappskog PM et al. (2001). A phenylalanine hydroxylase amino acid polymorphism with implications for molecular diagnostics. Mol. Genet. Metab. 73: 280-284.
27. Greeves LG, Patterson CC, Carson DJ, Thom R et al. (2000). Effect of genotype on changes in intelligence quotient after dietary relaxation in phenylketonuria and hyperphenylalaninaemia. Arch. Dis. Child. 82: 216-221.
28. Guldberg P, Rey F, Zschocke J, Romano V et al. (1998). A European multicenter study of phenylalanine hydroxylase deficiency: classification of 105 mutations and a general system for genotype-based prediction of metabolic phenotype. Am. J. Hum. Genet. 63: 71-79.
29. Harding CO, Wild K, Chang D, Messing A et al. (1998). Metabolic engineering as therapy for inborn errors of metabolism-development of mice with phenylalanine hydroxylase expression in muscle. Gene Ther. 5: 677-683.
30. Harding CO, Neff M, Jones K, Wild K et al. (2003). Expression of phenylalanine hydroxylase (PAH) in erythrogenic bone marrow does not correct hyperphenylalaninemia in Pah(enu2) mice. J. Gene Med. 5: 984-993.
31. Harding CO, Neff M, Wild K, Jones K et al. (2004). The fate of intravenously administered tetrahydrobiopterin and its implications for heterologous gene therapy of phenylketonuria. Mol. Genet. Metab. 81: 52-57.
32. Hennermann JB, Buhrer C, Blau N and Vetter B (2005). Long-term treatment with tetrahydrobiopterin increases phenylalanine tolerance in children with severe phenotype of phenylketonuria. Mol. Genet. Metab. (in press).
33. Ikeda K, Schiltz E, Fujii T and Takahashi M (2005). Phenylalanine ammonia-lyase modified with polyethylene glycol: Potential therapeutic agent for phenylketonuria. Amino Acids (in press).
34. Jennings IG, Cotton RG and Kobe B (2000). Structural interpretation of mutations in phenylalanine hydroxylase protein aids in identifying genotype-phenotype correlations in phenylketonuria. Eur. J. Hum. Genet. 8: 683-696.
35. Kanai Y and Endou H (2003). Functional properties of multispecific amino acid transporters and their implications to transporter-mediated toxicity. J. Toxicol. Sci. 28: 1-17.
36. Kasnauskiene J, Cimbalistiene L and Kucinskas V (2003). Validation of PAH genotype-based predictions of metabolic phenylalanine hydroxylase deficiency phenotype: investigation of PKU/MHP patients from Lithuania. Med. Sci. Monit. 9: CR142-CR146.
37. Kay MA and Nakai H (2003). Looking into the safety of AAV vectors. Nature 424: 251.
38. Kayaalp E, Treacy E, Waters PJ, Byck S et al. (1997). Human phenylalanine hydroxylase mutations and hyperphenylalaninemia phenotypes: a metanalysis of genotype-phenotype correlations. Am. J. Hum. Genet. 61: 1309-1317.
39. Kim W, Erlandsen H, Surendran S, Stevens RC et al. (2004). Trends in enzyme therapy for phenylketonuria. Mol. Ther. 10: 220-224.
40. Koch R, Moseley KD, Yano S, Nelson Jr M et al. (2003). Large neutral amino acid therapy and phenylketonuria: a promising approach to treatment. Mol. Genet. Metab. 79: 110-113.
41. Landolt MA, Nuoffer JM, Steinmann B and Superti-Furga A (2002). Quality of life and psychologic adjustment in children and adolescents with early treated phenylketonuria can be normal. J. Pediatr. 140: 516-521.
42. Lee PJ, Ridout D, Walter JH and Cockburn F (2005). Maternal phenylketonuria: report from the United Kingdom Registry 1978-97. Arch. Dis. Child. 90: 143-146.
43. Leuzzi V, Pansini M, Sechi E, Chiarotti F et al. (2004). Executive function impairment in early-treated PKU subjects with normal mental development. J. Inherit. Metab. Dis. 27: 115-125.
44. Levy HL (1999). Phenylketonuria: old disease, new approach to treatment. Proc. Natl. Acad. Sci. USA 96: 1811-1813.
45. Lin CM, Tan Y, Lee YM, Chang CC et al. (1997). Expression of human phenylalanine hydroxylase activity in T lymphocytes of classical phenylketonuria children by retroviral-mediated gene transfer. J. Inherit. Metab. Dis. 20: 742-754.
46. Lindner M, Haas D, Mayatepek E, Zschocke J et al. (2001). Tetrahydrobiopterin responsiveness in phenylketonuria differs between patients with the same genotype. Mol. Genet. Metab. 73: 104-106.
47. Liu J, Jia X, Zhang J and Xiang H (2002). Study on a novel strategy to treatment of phenylketonuria. Artif. Cells Blood Substit. Immobil. Biotechnol. 30: 243-257.
48. MacDonald A (2000). Diet and compliance in phenylketonuria. Eur. J. Pediatr. 159 (Suppl 2): S136-S141.
49. MacDonald A, Ferguson C, Rylance G, Morris AA et al. (2003). Are tablets a practical source of protein substitute in phenylketonuria? Arch. Dis. Child. 88: 327-329.
50. MacDonald A, Daly A, Davies P, Asplin D et al. (2004). Protein substitutes for PKU: what's new? J. Inherit. Metab. Dis. 27: 363-371.
51. Matalon R, Surendran S, Matalon KM, Tyring S et al. (2003). Future role of large neutral amino acids in transport of phenylalanine into the brain. Pediatrics 112: 1570-1574.
52. Merrick J, Aspler S and Schwarz G (2003). Phenylalanine-restricted diet should be life long. A case report on long-term follow-up of an adolescent with untreated phenylketonuria. Int. J. Adolesc. Med. Health 15: 165-168.
53. Moats RA, Moseley KD, Koch R and Nelson Jr M (2003). Brain phenylalanine concentrations in phenylketonuria: research and treatment of adults. Pediatrics 112: 1575-1579.
54. Nagasaki Y, Matsubara Y, Takano H, Fujii K et al. (1999). Reversal of hypopigmentation in phenylketonuria mice by adenovirus-mediated gene transfer. Pediatr. Res. 45: 465-473.
55. Oh HJ, Park ES, Kang S, Jo I et al. (2004). Long-term enzymatic and phenotypic correction in the phenylketonuria mouse model by adeno-associated virus vector-mediated gene transfer. Pediatr. Res. 56: 278-284.
56. Perez-Duenas B, Vilaseca MA, Mas A, Lambruschini N et al. (2004). Tetrahydrobiopterin responsiveness in patients with phenylketonuria. Clin. Biochem. 37: 1083-1090.
57. Pey AL, Desviat LR, Gamez A, Ugarte M et al. (2003). Phenylketonuria: genotype-phenotype correlations based on expression analysis of structural and functional mutations in PAH. Hum. Mutat. 21: 370-378.
58. Pietz J, Kreis R, Rupp A, Mayatepek E et al. (1999). Large neutral amino acids block phenylalanine transport into brain tissue in patients with phenylketonuria. J. Clin. Invest. 103: 1169-1178.
59. Przyrembel H and Bremer HJ (2000). Nutrition, physical growth, and bone density in treated phenylketonuria. Eur. J. Pediatr. 159 (Suppl 2): S129-S135.
60. Rivera I, Cabral A, Almeida M, Leandro P et al. (2000). The correlation of genotype and phenotype in Portuguese hyperphenylalaninemic patients. Mol. Genet. Metab. 69: 195-203.
61. Rohr FJ, Munier AW and Levy HL (2001). Acceptability of a new modular protein substitute for the dietary treatment of phenylketonuria. J. Inherit. Metab. Dis. 24: 623-630.
62. Rose WC, Leach BE, Coon MJ and Lambert GF (1955). The amino acid requirements of man. IX. The phenylalanine requirement. J. Biol. Chem. 213: 913-922.
63. Sarkissian CN, Shao Z, Blain F, Peevers R et al. (1999). A different approach to treatment of phenylketonuria: phenylalanine degradation with recombinant phenylalanine ammonia lyase. Proc. Natl. Acad. Sci. USA 96: 2339-2344.
64. Scriver CC (1998). A simple phenylalanine method for detecting phenylketonuria in large populations of newborn infants, by Robert Guthrie and Ada Susi, Pediatrics, 1963; 32: 318-343. Pediatrics 102: 236-237.
65. Scriver CR (2002). Why mutation analysis does not always predict clinical consequences: explanations in the era of genomics. J. Pediatr. 140: 502-506.
66. Scriver CR and Waters PJ (1999). Monogenic traits are not simple: lessons from phenylketonuria. Trends Genet. 15: 267-272.
67. Scriver CR and Kaufman S (2001). Hyperphenylalaninemia: phenylalanine hydroxylase deficiency. In: The metabolic and molecular bases of inherited disease (Scriver CR, Beaudet A, Sly WS and Childs, eds.). McGraw-Hill Inc., New York, NY, USA, pp. 1667-1724.
68. Scriver CR, Hurtubise M, Konecki D, Phommarinh M et al. (2003). PAHdb 2003: what a locus-specific knowledgebase can do. Hum. Mutat. 21: 333-344.
69. Smith I and Knowles J (2000). Behaviour in early treated phenylketonuria: a systematic review. Eur. J. Pediatr. 159 (Suppl 2): S89-S93.
70. Spaapen LJ and Rubio-Gozalbo ME (2003). Tetrahydrobiopterin-responsive phenylalanine hydroxylase deficiency, state of the art. Mol. Genet. Metab. 78: 93-99.
71. Start K (1998). Treating phenylketonuria by a phenylalanine-free diet. Prof. Care Mother. Child. 8: 109-110.
72. Steinfeld R, Kohlschutter A, Ullrich K and Lukacs Z (2003). A hypothesis on the biochemical mechanism of BH(4)-responsiveness in phenylalanine hydroxylase deficiency. Amino Acids 25: 63-68.
73. Steinfeld R, Kohlschutter A, Ullrich K and Lukacs Z (2004). Efficiency of long-term tetrahydrobiopterin monotherapy in phenylketonuria. J. Inherit. Metab. Dis. 27: 449-453.
74. Surtees R and Blau N (2000). The neurochemistry of phenylketonuria. Eur. J. Pediatr. 159 (Suppl 2): S109-S113.
75. Thony B, Ding Z and Martinez A (2004). Tetrahydrobiopterin protects phenylalanine hydroxylase activity in vivo: implications for tetrahydrobiopterin-responsive hyperphenylalaninemia. FEBS Lett. 577: 507-511.
76. Trefz FK and Blau N (2003). Potential role of tetrahydrobiopterin in the treatment of maternal phenylketonuria. Pediatrics 112: 1566-1569.
77. Waisbren SE, Mahon BE, Schnell RR and Levy HL (1987). Predictors of intelligence quotient and intelligence quotient change in persons treated for phenylketonuria early in life. Pediatrics 79: 351-355.
78. Walter JH, White FJ, Hall SK, MacDonald A et al. (2002). How practical are recommendations for dietary control in phenylketonuria? Lancet 360: 55-57.
79. Weglage J, Wiedermann D, Denecke J, Feldmann R et al. (2002). Individual blood-brain barrier phenylalanine transport in siblings with classical phenylketonuria. J. Inherit. Metab. Dis. 25: 431-436.